OTCMKTS:CYDY CytoDyn (CYDY) Stock Price, News & Analysis $0.12 0.00 (0.00%) (As of 11/21/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisChartEarningsFinancialsHeadlinesSEC FilingsShort Interest About CytoDyn Stock (OTCMKTS:CYDY) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get CytoDyn alerts:Sign Up Key Stats Today's Range$0.12▼$0.1250-Day Range$0.12▼$0.1752-Week Range$0.11▼$0.42Volume2.86 million shsAverage Volume2.57 million shsMarket Capitalization$144.01 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewCytoDyn Inc., a clinical-stage biotechnology company, engages in the development of treatments for multiple therapeutic indications. The company is involved in the clinical development of leronlimab, a novel humanized monoclonal antibody targeting the C-C chemokine receptor type 5 receptor in the areas of COVID-19, human immunodeficiency virus (HIV), Metabolic dysfunction-associated steatohepatitis (MASH), and solid tumors in oncology, such as metastatic triple-negative breast cancer. Its leronlimab is currently under phase 2 development for the treatment of NASH, HIV- NASH, and solid tumors, as well as under pre-clinical development for the treatment of HIV-PrEP and HIV-Cure. The company was formerly known as RexRay Corporation. CytoDyn Inc. was incorporated in 2002 and is based in Vancouver, Washington.Read More… 917 Trades… Zero Losses? (Ad)As you likely know, the “Trump bump” launched stocks to record highs after he secured his second reelection bid. Now, Trump and his team are coming to gut government regulation – and it’s going to create some incredible market opportunities. But while the masses chase large-cap tech and so-called AI stocks, a small circle of traders are using a strange but tactical method to find a pool of “hidden Trump trades.”Go here to see how you can start accessing these opportunities today CytoDyn Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks8th Percentile Overall ScoreCYDY MarketRank™: CytoDyn scored higher than 8% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for CytoDyn. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of CytoDyn is -5.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of CytoDyn is -5.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.36% of the outstanding shares of CytoDyn have been sold short.Short Interest Ratio / Days to CoverCytoDyn has a short interest ratio ("days to cover") of 2.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in CytoDyn has recently increased by 25.78%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCytoDyn does not currently pay a dividend.Dividend GrowthCytoDyn does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted1.36% of the outstanding shares of CytoDyn have been sold short.Short Interest Ratio / Days to CoverCytoDyn has a short interest ratio ("days to cover") of 2.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in CytoDyn has recently increased by 25.78%, indicating that investor sentiment is decreasing significantly. News and Social Media3.3 / 5News SentimentN/A News SentimentCytoDyn has a news sentiment score of 1.93. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.48 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for CytoDyn this week, compared to 0 articles on an average week.Search InterestOnly 1 people have searched for CYDY on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added CytoDyn to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, CytoDyn insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.54% of the stock of CytoDyn is held by insiders.Percentage Held by InstitutionsOnly 5.06% of the stock of CytoDyn is held by institutions.Read more about CytoDyn's insider trading history. Receive CYDY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CytoDyn and its competitors with MarketBeat's FREE daily newsletter. Email Address CYDY Stock News HeadlinesCytoDyn Announces FDA Clearance of Its Phase II Oncology TrialNovember 4, 2024 | globenewswire.comCytoDyn Appoints Dr. Melissa Palmer, M.D., as Lead Consultant in Hepatology; Announces Follow-Up Inflammation Studies with SMC LaboratoriesOctober 30, 2024 | globenewswire.comBuffett’s Selling Out: Is Your 401(k) About to Get Wiped Out?Let me share something important with you. Just a few weeks ago, Warren Buffett unloaded $932 million worth of bank stocks. He didn't do it on a whim—he knows something big is coming. The question is: Why aren't you taking action, too?November 22, 2024 | Golden Crest (Ad)CytoDyn Appoints Dr. Max Lataillade as Senior Vice President and Head of Clinical DevelopmentOctober 8, 2024 | finance.yahoo.comCytoDyn Announces Abstract that Highlights Leronlimab’s Potential in Mediating ART-Free Viral Control in Infant Rhesus MacaquesOctober 7, 2024 | finance.yahoo.comCytoDyn Announces Abstract that Highlights Leronlimab's Potential in Mediating ART-Free Viral Control in Infant Rhesus MacaquesOctober 7, 2024 | globenewswire.comCytoDyn Engages Syneos Health as CRO For Its Phase II Oncology TrialOctober 4, 2024 | globenewswire.comCytoDyn Announces Preliminary Findings in Study with SMC LaboratoriesSeptember 24, 2024 | globenewswire.comSee More Headlines CYDY Stock Analysis - Frequently Asked Questions How have CYDY shares performed this year? CytoDyn's stock was trading at $0.1950 at the start of the year. Since then, CYDY stock has decreased by 39.4% and is now trading at $0.1181. View the best growth stocks for 2024 here. How were CytoDyn's earnings last quarter? CytoDyn Inc. (OTCMKTS:CYDY) released its quarterly earnings results on Tuesday, October, 15th. The biotechnology company reported $0.02 earnings per share for the quarter. How do I buy shares of CytoDyn? Shares of CYDY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of CytoDyn own? Based on aggregate information from My MarketBeat watchlists, some other companies that CytoDyn investors own include American Water Works (AWK), Waste Connections (WCN), The RMR Group (RMR), Voyager Therapeutics (VYGR), DiamondRock Hospitality (DRH), AUO (AUOTY) and iShares Micro-Cap ETF (IWC). Company Calendar Last Earnings10/15/2024Today11/22/2024Fiscal Year End5/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolOTCMKTS:CYDY Previous SymbolNASDAQ:CYDY CUSIP23283M101 CIK1175680 Webwww.cytodyn.com Phone(360) 980-8524FaxN/AEmployees9Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.02) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-49,840,000.00 Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-129.84% Debt Debt-to-Equity RatioN/A Current Ratio0.40 Quick Ratio0.40 Sales & Book Value Annual Sales$270,000.00 Price / Sales533.35 Cash FlowN/A Price / Cash FlowN/A Book Value($0.11) per share Price / Book-1.07Miscellaneous Outstanding Shares1,219,350,000Free Float1,212,763,000Market Cap$144.01 million OptionableNot Optionable Beta0.17 A Beginner's Guide to Investing in CannabisUnlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.Get This Free Report This page (OTCMKTS:CYDY) was last updated on 11/22/2024 by MarketBeat.com Staff From Our Partners[Charles Payne Live Event] Click to Confirm Your RSVPThe Blueprint to Protect Your Portfolio Charles Payne reveals a strategy few investors know about Unstoppable Prosperity | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredHOTTEST TRADER IN AMERICA 🔥🔥🔥Ready for a rocket ride this weekend? After alerting his readers to a tiny $2 stock called Bright Minds Bio...Timothy Sykes | SponsoredBREAKING: NVDA loses $175 billion in 8 minutesIt's a wild week for the legendary chipmaker. Nvidia just beat earnings expectations across every metric, w...Chaikin Analytics | SponsoredFinancial Prophecy The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredBuffett Dumps $982 Million in BofA Stock—What Does He Know?Buffett's been eerily quiet about his reasons, but his actions speak volumes. When someone with his track reco...Genesis Gold Group | SponsoredCritical warning from the mountains of CarolinaNvidia CEO Jensen Huang says Big Tech will spend over $1 trillion on data centers. And that still might not...Weiss Ratings | SponsoredBuffett’s Selling Out: Is Your 401(k) About to Get Wiped Out?Let me share something important with you. Just a few weeks ago, Warren Buffett unloaded $932 million worth of...Golden Crest | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CytoDyn Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share CytoDyn With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.